X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Insights

BioSpain 2014 Expands its Investment Forum Through Wider Range of Investor Profiles and more Participating Companies

Yuvraj_pawp by Yuvraj_pawp
17th July 2014
in Insights

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Biospain 2014 is currently seeking and selecting projects for presentation as part of its Investment Forum, one of the most high profile in the sector, for which 25 investment funds – 70% of which are international- have already confirmed their attendance, a figure the organisers expect to double.

     (Logo: http://photos.prnewswire.com/prnh/20140716/697032 )

This year the Forum will be bolstered by the presence of a wider range of investor profiles, a bigger international presence and more participating companies.  

There are currently 10 available slots for companies and other entities wishing to pitch a business plan to the attending investors. In total, there will be 40 presentations over the three day duration of Biospain, each lasting 8-10 minutes, with alternating conferences on a wide range of investment issues (including corporate funds for big pharma, large international funds, PPP initiatives, business angels, industrial capital from non-pharma sectors and crowdfunding, to name a few).    

Among the most important funds to attend Biospain feature companies such as Aravis Ventures (Switzerland), Caixa Capital Risc (Spain), Cross Road Biotech (Spain), Edmond de Rothschild Investment  Partners (France), Forbion Capital Partners (Netherlands), Index Ventures (Switzerland), Johnson & Johnson Development Corporation (UK), LG Life Sciences (South Korea), Merck Serono Ventures (Germany), Novartis Venture Fund (Switzerland), Sofinnova Partners (France), Takeda Ventures (US), Ysios Capital Partners (Spain), Glaxo SmithKline Pharmaceuticals (UK) y Warburg Pincus (UK).

BioSpain 2014 (http://www.biospain2014.org), the 7th International Biotechnology Conference, is a biennial event which will take place from the 24th to the 26th of September in the Palacio de Congresos y Exposiciones de Galicia (Galicia Conference Centre), Santiagode Compostela (A Coruña). It is organised by the Spanish Bioindustry Association (ASEBIO) and on this edition, also by the Autonomous Government of Galicia, the University of santiago de Compostela, the University of Vigo and Santiago City Council.

Stand space at the trade fair is experiencing high demand, with 80% already allocated to exhibitors.  

So far we can confirm the attendance of over 100 companies and other entities from 20 countries, including delegations from countries such as Portugal, Canada, Colombia, Mexico, Russia, the UK and India. Biospain expects to attract 2000 participants – 10% more than in 2012 – exceeding the benchmark set that year of 800 companies and institutions from 40 countries.

BioSpain 2014 is sponsored by Bioibérica, Merck, MSD, Zeltia Group, Roche Institute and CLAMBER (Castilla La Mancha Bioeconomy Region).

Lucía Cecilia
Head of Communications for BioSpain 2014 and ASEBIO
landline. + 34-912109374/10
mobile: + 34-663 117-293    
e-mail: lcecilia@asebio.com / lcecilia@biospain2014.org

SOURCE ASEBIO (Spanish Bioindustry Association)

Previous Post

Lophius Biosciences Launches Interactive T CELL TOOLS Product Finder and Online Order Portal

Next Post

CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands

Related Posts

wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
high volume injectable formulations
Insights

Overcoming Challenges in High-Volume Injectable Formulations

27th September 2025
Insights

Smart Drug Delivery Systems for Patient Care

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
active pharmaceutical ingredients supply chain
Drug Development

Future of Active Pharmaceutical Ingredients Supply

26th September 2025
pharmaceutical excipients for new therapies
Drug Development

Advances in Pharmaceutical Excipients for New Therapies

26th September 2025
Next Post

CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In